As a company that is constantly developing and extending its range of healthcare products, it is important to keep both customers, distributors, medical professionals, patients and shareholders up to date with the latest MDI developments. Along with the latest product and industry news, information for professional healthcare workers such as upcoming conferences and tradeshows where MDI will be represented, will be posted here. As this page will be continually updated, please visit here regularly to see the latest news.
News
Appointment of Non Executive Director – Christine Emmanuel
26 May 2020 ASX ANNOUNCEMENT Appointment of Non-Executive Director – Christine Emmanuel Medical Developments InternationPenthrox approved in Hungary
25 May 2020 ASX Announcement Penthrox approved in Hungary Medical Developments International Limited (ASX: MVP) is deligPenthrox approved in The Netherlands and Bosnia & Herzegovina
5 May 2020 ASX Announcement Penthrox approved in The Netherlands and Bosnia & Herzegovina. Medical Developments IntePenthrox is approved in Thailand
28 April 2020 ASX Announcement Penthrox is approved in Thailand Medical Developments International Limited (ASX: MVP), aFY20 Half Year Report and Accounts
19 February 2020 ASX ANNOUNCEMENT MVP has today released its FY20 Half Year Report and Accounts. Please refer to the folPenthrox Marketing Authorisation Application in Russia
6 December 2019 ASX ANNOUNCEMENT Penthrox Marketing Authorisation Application in Russia Medical Developments InternationPenthrox IND approved in China
21 November 2019 ASX ANNOUNCEMENT Penthrox IND approved in China Medical Developments International Limited (ASX: MVP) iMVP signs new Manufacturing Development Project with CSIRO
29 October 2019 ASX ANNOUNCEMENT MVP signs new Manufacturing Development Project with CSIRO Medical Developments InternaPenthrox approved in EUSEM guidelines
24 October 2019 ASX Announcement Penthrox® entered in the European Society of Emergency Medicine (EUSEM) guidelines as nPenthrox is launched in Italy
23 October 2019 ASX Announcement Penthrox? is launched in Italy Medical Developments International Ltd (ASX: MVP) is delPositive study results for Penthrox in Europe
22 October 2019 ASX Announcement Positive study results for Penthrox? demonstrating superiority over Standard of Care foPreliminary Final Report and Full Year Accounts
21 August 2019 ASX Announcement Preliminary Final Report and Full Year Accounts For the full report please clickPenthrox USA Update
19 July 2019 ASX Announcement Penthrox – USA Update Medical Developments International Limited (ASX: MVP) advisesLicensing deal for Penthrox in Australia
3 June 2019 ASX ANNOUNCEMENT Licensing deal for Penthrox in Australia Medical Developments International Limited (ASX: MMVP – Half Year Report and Accounts
20 February 2019 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments InternationaTrading and Market Update
30 October 2018 ASX Announcement Trading and market update Please refer to the following link for a trading and market uChairman’s and CEO’s Address to Shareholders
Please refer to the following link for the Chairman’s and CEO’s Address to Shareholders, as provided at thePenthrox is approved in Saudi Arabia
11 October 2018 ASX Announcement Penthrox is approved in Saudi Arabia Medical Developments International Limited (ASX:MVMVP signs exclusive Penthrox deal for China
8 October 2018 ASX Announcement MVP signs exclusive Penthrox deal for China with Daiichi Sankyo Medical Developments IntShare Purchase Plan
19 September 2018 ASX Announcement Share Purchase Plan Medical Developments International (ASX: MVP) (Company) advises tPenthrox: USA update
29 August 2018 ASX Announcement Penthrox: USA update Medical Developments International Limited (ASX: MVP) advise that iPreliminary Final Report and Full Year Accounts
17 August 2018 ASX Announcement Preliminary Final Report and Full Year Accounts For the full report please clickCapital Raising – Placement and Share Purchase Plan
8 August 2018 ASX ANNOUNCEMENT Capital Raising – Placement and Share Purchase Plan 1. Placement Medical DevelopmenFY18 Results Update
For the full ASX Announcement “FY18 Results Update” please click on the following link:ASX AnnouncementUSA Update
25 July 2018 ASX ANNOUNCEMENT USA Update Medical Developments International (ASX: MVP) today advised that it met with thPenthrox approved in Italy, The Czech Republic and Spain
16 July 2018 ASX Announcement Penthrox approved in Italy, The Czech Republic and Spain. Medical Developments InternationPenthrox approved in Portugal and Switzerland
25 June 2018 ASX Announcement Penthrox approved in Portugal and Switzerland. Medical Developments International LimitedMVP signs exclusive Distribution Deal for Iran
29 May 2018 ASX Announcement MVP signs exclusive Distribution Deal for Iran. Penthrox approved in Romania, Bulgaria, SloTrading Update
14 May 2018 ASX Announcement Trading Update Medical Developments International Limited (ASX: MVP) CEO, Mr. John Sharman,Penthrox approved in Finland
24 April 2018 ASX Announcement Penthrox approved in Finland Medical Developments International Limited (ASX: MVP) is delPenthrox is approved in Canada
10 April 2018 ASX Announcement Penthrox is approved in Canada Medical Developments International Limited (ASX:MVP), annoPenthrox approved in Germany
5 April 2018 ASX Announcement Penthrox approved in Germany Medical Developments International Limited (ASX: MVP) is deliPenthrox approved in Sweden, Norway, Poland and Croatia
27 March 2018 ASX Announcement Penthrox approved in Sweden, Norway, Poland and Croatia Medical Developments InternationaCEO Roadshow Presentation
26 February 2018 ASX Announcement Please refer to the attached link for the latest version of the CEO Roadshow PresentatStage II success for new manufacturing technology – Lidocaine
20 February 2018 ASX ANNOUNCEMENT ?Stage II success for new manufacturing technology: Lidocaine Medical Developments IntFirst Penthrox order received for Austria
19 February 2018 ASX Announcement Penthrox : First order received for Austria Medical Developments International LimitedPenthrox approved in Estonia
19 February 2018 ASX Announcement Penthrox approved in Estonia Medical Developments International Limited (ASX: MVP) isMVP – Half Year Report and Accounts
16 February 2018 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments InternationaMVP signs major deal with Walgreens in the USA
12 February 2018 ASX ANNOUNCEMENT MVP signs major deal with Walgreens in the USA Medical Developments International LimiPenthrox approved in Austria
29 January 2018 ASX Announcement Penthrox approved in Austria Medical Developments International Limited (ASX: MVP) is dPenthrox approved in Iceland
22 January 2018 ASX Announcement Penthrox approved in Iceland Medical Developments International Limited (ASX: MVP) is dASX Announcement: Penthrox approved in another 22 European countries
12 December 2017 ASX Announcement Penthrox approved in another 22 European countries Medical Developments InternationalAGM – Chairman’s and CEO’s Address to Shareholders
27 October 2017 ASX ANNOUNCEMENT Chairman?s and CEO?s Address to Shareholders MVP today held its? 2017 AGM. Please referPenthrox approved in Mexico
18 October 2017 ASX ANNOUNCEMENT Penthrox approved in Mexico Medical Developments International Limited (ASX: MVP) is dePenthrox is recommended for use in all UK ambulances
26 September 2017 ASX ANNOUNCEMENT Penthrox is recommended for use in all UK ambulances Medical Developments InternationCEO Roadshow Presentation
18 August 2017 ASX announcement Please find attached a link to the latest CEO Roadshow Presentation Road Show PresentatiMVP FY17 Preliminary Final Report & Full Year Accounts
18?August 2017 ASX ANNOUNCEMENT Medical Developments International Limited (ASX: MVP) is delighted to announce the releaMVP signs Respiratory Device supply deal with Sam’s Club
2 August 2017 ASX ANNOUNCEMENT MVP signs Respiratory Device supply deal with Sam?s Club Medical Developments InternationPenthrox Regulatory Dossier accepted for review in Canada
15 June 2017 ASX ANNOUNCEMENT Penthrox Regulatory Dossier accepted for review in Canada Medical Developments InternationPresentation at Jefferies 2017 Global Healthcare Conference – June 9, New York
8 June 2017 ASX ANNOUNCEMENT Presentation at Jefferies 2017 Global Healthcare Conference – June 9, New York Medical DevePresentation at Jefferies 2017 Global Healthcare Conference – June 9, New York
8 June 2017 ASX ANNOUNCEMENT Presentation at Jefferies 2017 Global Healthcare Conference – June 9, New York MedicaMVP signs significant Manufacturing Development Project with CSIRO
5 June 2017 ASX ANNOUNCEMENT MVP signs significant Manufacturing Development Project with CSIRO. Medical Developments InPenthrox replaces Nitrous Oxide in New Zealand Ambulance
2 June 2017 ASX ANNOUNCEMENT Penthrox replaces Nitrous Oxide in New Zealand Ambulance Medical Developments InternationalMVP Respiratory Devices now available in Costco and circa 10,000 USA pharmacies
27 April 2017 ASX ANNOUNCEMENT MVP Respiratory Devices now available in Costco and circa 10,000 USA pharmacies Medical DPenthrox licensing deal for Russia
12 April 2017 ASX ANNOUNCEMENT Penthrox licensing deal for Russia Medical Developments International Limited (ASX: MVP)MVP’s Respiratory Devices in all Kmart pharmacies in the USA
10 April 2017 ASX ANNOUNCEMENT MVP’s Respiratory Devices in all Kmart pharmacies in the USA. Medical Developments InternMVP’s Respiratory Devices in all Kmart pharmacies in the USA
10 April 2017 ASX ANNOUNCEMENT MVP’s Respiratory Devices in all Kmart pharmacies in the USA. Medical DevelopmentsMVP’s Respiratory Devices in all Walmart stores in the USA
10 April 2017 ASX ANNOUNCEMENT MVP’s Respiratory Devices in all Walmart stores in the USA. Medical Developments InternatMVP?s Respiratory Devices in all Walmart stores in the USA
10 April 2017 ASX ANNOUNCEMENT MVP?s Respiratory Devices in all Walmart stores in the USA. Medical Developments InternatPenthrox: Second Order for UK and Ireland
2 March 2017 ASX ANNOUNCEMENT Penthrox: Second order for UK and Ireland Medical Developments International Limited (ASX:FY17 HY Results
20th February 2017 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments InternatioPenthrox Launched in France and Belgium and first sales
8 February 2017 ASX ANNOUNCEMENT Penthrox launched in France and Belgium and first sales. Medical Developments InternatiPenthrox – European Update
7 February 2017 ASX ANNOUNCEMENT Penthrox: European update Medical Developments International Limited (ASX: MVP) provideMVP CEO Claims Award
23 December 2016 PRESS RELEASE MVP CEO wins Biotech Daily 2016 CEO of the Year??????????????????????????????????????????Penthrox approved for sale in Taiwan
8 December 2016 ASX ANNOUNCEMENT Penthrox approved for sale in Taiwan Medical Developments International Limited (ASX: MPenthrox submitted for Regulatory Approval in 22 European Countries
29 November 2016 ASX ANNOUNCEMENT PENTHROX SUBMITTED FOR REGULATORY APPROVAL IN 22 EUROPEAN COUNTRIES Medical DevelopmenPOST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order
14 November 2016 POST TRUMP: Business as usual – MVP signs a Respiratory deal and receives first order Medical DevMVP signs major deal with CSIRO
28 October 2016 MVP signs major deal with CSIRO on exclusive rights for some key drugs Medical Developments InternationaMVP FY16 Annual Report and AGM Notice of Meeting
Please refer to the following link for a copy of the?MVP FY16 Annual Report Also attached is a link to the MVP AGM NOMMVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox in Canada
12 September 2016 MVP Signs Exclusive Licensing and Distribution Agreement with Purdue Pharma Canada for Penthrox? in CaPenthrox receives regulatory approval in the UAE
9 September 2016 ASX ANNOUNCEMENT Penthrox receives regulatory approval in the UAE Medical Developments International LiASX Announcement – Licensing deal for Korea
6 September 2016 ASX ANNOUNCEMENT Licensing deal for Korea Medical Developments International Limited (?MDI?) (ASX: MVP)FY16 Full Year Results
18 August 2016 ASX ANNOUNCEMENT FY16 Full Year Results For details relating to the full ASX Release, please click on theEuropean Penthrox Update
12 August 2016 ASX ANNOUNCEMENT European Penthrox? Update. Medical Developments International Limited (ASX: MVP) advisesUSA Penthrox Update & USA Respiratory Update
9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical DUSA Penthrox Update & USA Respiratory Update
9 August 2016 ASX ANNOUNCEMENTS – USA Penthrox Update & USA Respiratory Update USA : Penthrox update Medical DVive La France: Regulatory Approval Received
21 June 2016 ASX ANNOUNCEMENT Vive La France: Regulatory Approval Received Medical Developments International Limited (ALicensing deal for Canada
14 June 2016 ASX ANNOUNCEMENT ? Licensing deal for Canada Medical Developments International Limited (ASX: MVP) iMVP signs Respiratory deals in the United States and Portugal
25 May 2016 ASX ANNOUNCEMENT MVP signs Respiratory deals in the United States and Portugal Medical Developments InternatBell Potter and Patersons Initiate Coverage on MVP
Bell Potter and Patersons has recently initiated coverage on Medical Developments International (ASX:MVP). ?For a copy oHalf Year Report 2015-16
18 February 2016 HALF YEAR REPORT 2015-2016 For a copy of the Half Year Report 2015-16, please click on the following liMVP Completes Acquisition of Breath-A-Tech
5 February 2016 ASX ANNOUNCEMENT MVP Completes Acquisition of Breath-A-Tech Medical Developments International Limited (ASX:MVP Shareholder News – January 2016
To read?our first edition of ASX:MVP Shareholder News, click on the link:?Shareholder News January 2016?Penthrox Launch in the UK and Pricing Approval for Ireland
27 January 2016 ASX ANNOUNCEMENT Penthrox Launch in the UK and Pricing Approval for Ireland Medical Developments InternaFDA Approves New Range of Respiratory Devices
27 January 2016 ASX ANNOUNCEMENT FDA Approves New Range of Respiratory Devices Medical Developments International LimiteMVP acquires Avita Medical’s Australian Respiratory Business
24 December 2015 ASX ANNOUNCEMENT MVP acquires Avita Medical’s Australian Respiratory Business Medical Developments InteMVP acquires Avita Medical?s Australian Respiratory Business
24 December 2015 ASX ANNOUNCEMENT MVP acquires Avita Medical?s Australian Respiratory Business Medical Developments InteASX Announcement: Green Whistle receives regulatory and marketing approval in the United Kingdom
28 October 2015 ASX ANNOUNCEMENT Green Whistle receives regulatory and marketing approval in the United Kingdom MedicalGreen Whistle receives regulatory approval in Singapore
23 September 2015 ASX ANNOUNCEMENT ?Green Whistle receives regulatory approval in Singapore Medical Developments InternaMVP completes European Distribution deal with Mundipharma
14 September 2015 ASX ANNOUNCEMENT Mundipharma and Medical Developments International announce a new alliance for the coFY15 Chairman/CEO Report and Annual Accounts
21 August 2015 ASX ANNOUNCEMENT Preliminary Final Report and Full Year Accounts Medical Developments International LimitMajor licensing deal for Europe
29 June 2015 ASX ANNOUNCEMENT Major licensing deal for Europe Medical Developments International Limited (ASX: MVMore Penthrox Licensing Agreements Expected
12 May 2015 ASX ANNOUNCEMENT More Penthrox Licensing Agreements Expected To facilitate distributing Penthrox internationNear term planning for the globalisation of Penthrox
8 May 2015 ASX ANNOUNCEMENT Near term planning for the globalisation of Penthrox The approval of Penthrox for use in thePenthrox Regulatory Approval in UK and Europe
6 May 2015 ASX Announcement Penthrox successfully completes its Decentralised Regulatory Approval Procedure in Europe MeTrading Update – 1 May 2015
Trading Update – 1 May 2015FY15 Half Year Results
MDI FY15 HY Report (Final)ASX Announcement – Green Whistle: Positive “Regulatory Approval” feedback from European Regulatory Authorities
Medical Developments International Limited (ASX:MVP) is delighted to announce that it has received positive feedback froASX Announcement – Green Whistle: Positive ?Regulatory Approval? feedback from European Regulatory Authorities
Medical Developments International Limited (ASX:MVP) is delighted to announce that it has received positive feedback froASX Announcement – Major European deal for Penthrox
Medical Developments International (MVP) is delighted to announce it has entered into an exclusive Distribution, LicenseASX Announcement – Supply Agreement for Respiratory Products in the UK
Medical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK toASX Announcement ? Supply Agreement for Respiratory Products in the UK
Medical Developments International (MVP) is delighted to advise it has entered into an exclusive agreement with PSUK toTrial conducted to evaluate newer methods of pain relief for limb injuries
SINGAPORE: A year-long trial is being conducted on two medications to ensure patients get a faster and more effective deASX Announcement – Green Whistle receives regulatory approval in South Africa
Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in SASX Announcement: Overseas Registration and Partnership Update
Update on European Marketing Application In November 2013, Medical Developments International (MVP) submitted its regulaASX Announcement – Successful Clinical Study Results
?THOROUGH QT/QTc? PENTHROX? CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES Medical DevelopmentsCSIRO Successful completion of first milestone
In August 2012 MVP announced it had entered into a research and development program with the CSIRO designed to introduceChairman’s and CEO’s Report
Download CEO’s & Chairman’s Report as PDF RECORD PROFIT STRONG GROWTH AND 3 CENTS FULLY FRANKED INTERIMASX Announcement
20 January 2013 ASX ANOUNCEMENT RESULTS OF PIVOTAL PHASE III CLINICAL TRIAL Methoxyflurane inhalation demonstrated to beASX Announcement
27 December 2012 ASX ANNOUNCEMENT Significant Developments and Opportunities in Asthma Devices Consistent with MVP?s strASX Announcement
2012 Annual General Meeting Address to Shareholders by Chairman and CEO 24 October, 2012 ADDRESS BY CHAIRMAN ? MR. DAVIDCHAIRMAN’S AND CEO’S REPORT
CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (“MDI”) (ASX:MVP) delivered a Record NetCHAIRMAN?S AND CEO?S REPORT
CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (?MDI?) (ASX:MVP) delivered a Record NetLAST PATIENT ENROLLED: EUROPEAN PHASE III PIVOTAL TRIAL COMPLETED
Medical Developments International Limited (ASX: MVP) is delighted to confirm the 300th and final patient has been enrolFURTHER EARNINGS GUIDANCE
The Board of Directors of Medical Developments International Ltd. (ASX:MVP) announced a profit guidance upgrade on 22 JuMEDICAL DEVELOPMENTS EXPANDS INTO EUROPE
Medical Developments is pleased to announce it has established a UK subsidiary company and appointed a European BusinessFurther Earnings Guidance The Board of Directors of Medical Developments International Ltd. (ASX:MVP) advise the marketDRP Results
Medical Developments is delighted to confirm the following results from its Interim Dividend declared on 23 February, 20